Huron Consulting Group (HURN): The Buyback Math Looks Better Than the Valuation Gap

Huron Consulting Group (HURN) closed around $152 on August 7 — roughly 30% above the $116 level where it sat when the Q2 2026 earnings report landed on July 28. That move is the market's version of a vote of confidence. It's also the reason the question of whether this stock is undervalued deserves a different framing than the headline implies.

The earnings report was strong. Revenue before reimbursables grew 15.7% year-over-year to $465.6 million, with 10.8% of that coming from organic demand. Adjusted EBITDA... climbed to $72.6 million and the margin expanded to 15.6% from 15.1% a year earlier. Adjusted EPS of $2.46 beat consensus by $0.29. Utilization rates in both consulting and digital segments jumped to above 81%, up from the mid-77% range a year ago.

The rally is a reaction to that report card. But a rally is also a rerating. And when the rerating is already underway, the undervalued label needs the same scrutiny as the numbers that sparked the move.

Valuation, Before and After the Move

At the late-July price, HURN traded at roughly 17.1x trailing earnings. That was below the professional services industry average of about 22.1x and well beneath the broader peer group average of 43.4x, which is pulled up by large-cap tech-adjacent consultancies like Accenture and Cognizant. A fair-value P/E estimate based on Huron's sector, margins, size, and risk profile came in around 22.6x, which made the late-July pricing look compelling — and that's exactly what it was.

At $152, the trailing P/E has expanded toward that 22x range. The valuation discount to the industry average has mostly closed. A stock doesn't need to be expensive to lose its margin of safety; it just needs to stop being cheap. The 6-of-6 undervaluation screen that read green in July is worth re-checking before treating it as a permanent characteristic.

The closest pure-play comparison is FTI Consulting (FCN), a mid-cap advisory firm with a similar mix of professional and forensic services. FTI trades around 23x trailing earnings and posted 9.5% revenue growth in its most recent quarter. Huron's growth rate is nearly double that, which is the fundamental reason it deserves a higher multiple. But the premium can't stretch indefinitely unless the growth stays that fast.

The Buyback Engine

Here's where the story gets interesting. In Q1 2026, Huron repurchased 1.1 million shares for $155.5 million. In Q2, it bought back another 438,456 shares for $52.6 million. Combined, that's roughly $208 million of buybacks in the first half of the year. About 49% of the current buyback program has already been retired.

Now compare that to the earnings base. HURN's GAAP net income for the first half was roughly $54 million ($23.2 million in Q1, $31.2 million in Q2). The company spent nearly four times its net income on share repurchases in six months. That kind of capital allocation is aggressive by design — it amplifies EPS growth even when organic earnings don't move — but it also means the balance sheet is doing heavy lifting to fund it. The buyback program is a mechanical tailwind for per-share metrics, which is why the EPS guidance of $9.00 to $9.40 for FY 2026 already bakes in continued repurchases.

The practical question for the investor is whether the buyback pace is sustainable at these prices. When you're buying back shares at $140-150, each dollar of repurchase retires fewer shares than it would have at $110. The program has room to run, but the math gets less efficient as the price climbs.

What the Segment Numbers Actually Say

Healthcare remains the anchor, representing half of year-to-date revenue and growing 17.4% in Q2. The segment operates at a 30.1% operating margin, which is the kind of profitability that supports a premium valuation. The growth engine here is regulatory pressure and labor shortages in healthcare delivery, forcing providers to outsource optimization and care-redesign work — exactly Huron's wheelhouse.

Commercial is the faster mover at 24.6% growth, with the segment margin expanding to 21.0% from 16.6% a year earlier. That 440-basis-point margin expansion is the operating leverage that makes the full story defensible. Digital bookings grew more than 20% in the first half, with over 60% of them involving direct or AI-enabled work — a detail that signals the company isn't just riding a buzzword but actually embedding AI into its service delivery.

The Counterargument

The bear case isn't about the quality of the results; it's about whether the first-half momentum carries through the back half of the year. Project-based consulting is cyclical at the margin. The company has been acquiring — the RelateCare purchase in June added roughly $30 million in annual revenue and 1,100 professionals, which inflates top-line growth but also creates integration risk. And the healthcare funding environment, while currently supportive, can shift on budget cycles. If utilization rates slip back toward the mid-70s, or if pricing pressure hits the commercial segment, the margin expansion story narrows fast.

Where This Fits

Huron belongs in a growth-adjacent sleeve — the kind of holding you own when you want exposure to professional services growth without paying large-cap tech multiples. The healthcare anchor provides durability. The buyback program provides mechanical EPS support. The utilization recovery provides a real operating story behind the earnings beats.

But the positioning trigger is the valuation gap, and that gap has narrowed. A stock at 21-22x trailing earnings with 12% revenue growth and 15% EBITDA margins is fairly priced, not cheap. The buyback activity makes the per-share story look better than the revenue story alone, which is a feature, not a bug — but it means you're partly dependent on management continuing to deploy capital aggressively at current levels.

What would change the call further? If the stock pulls back to the $120-130 range, the P/E compression would re-open the valuation gap and make the setup closer to what it looked like on July 28. If it continues above $155 without a corresponding acceleration in the back-half guidance, you're paying fair price for good — and that's a different proposition than buying a stock that the numbers genuinely suggest is undervalued.